3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
8
Condylomata Acuminata
7
Papillomavirus Infections
5
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Uterine Cervical Dysplasia
1
Neoplasms
1
Cancer Survivor
1
Interventions
Colposcopy
9
Imiquimod
7
Conization
7
Papillomavirus Vaccines
6
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
6
Cryotherapy
6
human papillomavirus vaccine, L1 type 16, 18
4
Blood Specimen Collection
4
Vaginal Smears
3
Vaccines
3
Papanicolaou Test
3
VGX-3100
2
Topotecan
2
Proflavine
2
Polymerase Chain Reaction
2
Paclitaxel
2
Mass Screening
2
Human Papillomavirus DNA Tests
2
Fluorouracil
2
Cisplatin
2
Biopsy
2
Acetic Acid
2
4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone
2
terameprocol
1
poly(gamma-glutamic acid)
1
methyl 5-aminolevulinate
1
lime
1
human papillomavirus vaccine, TA
1
hecolin
1
fludarabine phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Uterine Cervical Dysplasia
×
Vaccines, Synthetic
×
Clear all
NCT03493542
2024-12-31
V501-213
Merck Sharp & Dohme LLC
Phase 3
Completed
766 enrolled
38 charts